CLINICAL AND EPIDEMIOLOGICAL RESEARCH

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

C Salliot¹, D van der Heijde²

¹ Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
² Rheumatology Department, Leiden University Medical Centre, Leiden, The Netherlands

Dr C Salliot, Hôpital Cochin, service de Rhumatologie B, rue du faubourg Saint-Jacques, 75014 Paris, France; carinesalliot{at}gmail.com

Objective: To perform a systematic literature review of the long-term safety of methotrexate (MTX) monotherapy in rheumatoid arthritis (RA).

Methods: A search was performed in Medline, Cochrane and EMBASE. Adults with RA who had received MTX monotherapy for more than 2 years were studied.

Results: 88 published studies were included. Over 12 years of treatment, the termination rate of MTX due to toxicity was less than for sulfasalazine, gold, D-penicillamine and higher than for hydroxychloroquine (level of evidence 2a–2b). Long-term use of MTX does not appear to be a risk factor for serious infections, including herpes zoster (2b–4), and could provide a survival benefit by reducing cardiovascular mortality (2b). The prevalence of raised liver enzymes (more than twice the upper limit of normal) is close to 13% of patients; 3.7% of patients stopped MTX permanently owing to liver toxicity (2b). Data on the risk for liver fibrosis/cirrhosis are conflicting: a meta-analysis showed an incidence of fibrosis of 2.7% after 4 years of MTX (2a). However, two other studies on sequential liver biopsies did not show evidence for developing severe damage (2b). Insufficient data are available to fully assess the risk of lymphoma and malignancies, although there is no strong evidence of increased risk (2b–4).

Conclusion: This systematic literature search on MTX monotherapy with relatively low-dose use during at least 2 years shows favourable long-term safety.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Methotrexate: the gold standard without standardisation

Jonathan Kay and Rene Westhovens
Ann Rheum Dis 2009 68: 1081-1082. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Kay, J., Westhovens, R. (2009). Methotrexate: the gold standard without standardisation. Ann Rheum Dis 68: 1081-1082 [Full Text]  
• Visser, K, Katchamart, W, Loza, E, Martinez-Lopez, J A, Salliot, C, Trudeau, J, Bombardier, C, Carmona, L, van der Heijde, D, Bijlsma, J W J, Boumpas, D T, Canhao, H, Edwards, C J, Hamuryudan, V, Kvien, T K, Leeb, B F, Martin-Mola, E M, Mielants, H, Muller-Ladner, U, Murphy, G, Ostergaard, M, Pereira, I A, Ramos-Remus, C, Valentini, G, Zochling, J, Dougados, M (2009). Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68: 1086-1093 [Abstract] [Full Text]  
• Jarvelainen, H., Sainio, A., Koulu, M., Wight, T. N., Penttinen, R. (2009). Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy. Pharmacol. Rev. 61: 198-223 [Abstract] [Full Text]